Abstract
Immunotherapy is moving forward in prostate cancer. The autologous vaccine, Sipuleucel-T has been the first vaccine to be approved by FDA. First results with GVAX, tasquinimob or anti-PD-1 have been disappointing. Ipilimumab seen to be more active at an earlier stage of prostate disease. Identifying predictive factor or surrogate markers of activity of immunotherapy and which agents are clinically effective alone or in combination with others therapies such as hormonal or bone targeted therapies are warranted.
Keywords:
Checkpoint inhibiteurs; Checkpoint inhibitor; Urologie; Urology; Vaccines; Vaccins.
© 2016 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Cancer Vaccines / therapeutic use*
-
Cell Cycle Checkpoints / drug effects
-
Humans
-
Immunomodulation / immunology
-
Immunotherapy / methods*
-
Ipilimumab
-
Lenalidomide
-
Male
-
Nivolumab
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Prostatic Neoplasms / pathology
-
Prostatic Neoplasms / therapy*
-
Quinolines / therapeutic use
-
Quinolones
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Tissue Extracts / therapeutic use
-
Vaccines, Synthetic / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Cancer Vaccines
-
GVAX vaccine
-
Ipilimumab
-
PDCD1 protein, human
-
PROSTVAC
-
Programmed Cell Death 1 Receptor
-
Quinolines
-
Quinolones
-
Tissue Extracts
-
Vaccines, Synthetic
-
Nivolumab
-
Thalidomide
-
tasquinimod
-
sipuleucel-T
-
Lenalidomide